BCA
ALXN

Bay Colony Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Bay Colony Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,949
Closed -$617K – 350
2020
Q4 		$617K Buy
3,949
+100
+3% +$12.8K 0.33% 98
2020
Q3 		$440K Buy
+3,849
New +$415K 0.27% 113
2018
Q3 		– Sell
-181
Closed -$22K – 977
2018
Q2 		$22K Buy
+181
New +$21.2K 0.02% 511

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bay Colony Advisors's ALXN Position: Q1 2021 in Review

Bay Colony Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 3,949 shares — an estimated $617K sold.

Bay Colony Advisors first reported a position in ALXN in Q2 2018 and held it in 3 quarters. The position peaked at $617K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Bay Colony Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Bay Colony Advisors sold 3,949 Alexion Pharmaceuticals shares in Q1 2021, an estimated $617K.
  • Bay Colony Advisors first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Bay Colony Advisors's Alexion Pharmaceuticals position peaked at $617K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Bay Colony Advisors's 13F filing for Q1 2021, filed 13 May 2021.